Everolimus (RAD001) is an orally administered mTOR inhibitor that is well known for its antitumor efficacy and that has been approved for the treatment of several solid tumors, including renal cell carcinoma. The gene discussed is MTOR; the disease is hereditary clear cell renal cell carcinoma.